News UK modernises gene therapy definition in regulatory revamp The UK is planning changes to the definition of gene therapies and other genetic medicines, moving to a mechanism-based approach aligned with the EU.
News FDA won't approve Summit, Akeso's ivonescimab The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
R&D Inspection readiness is now a commercial question Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.
News Are Makary's priority review vouchers about to be canned? Reports are emerging that the national priority voucher scheme launched by former FDA chief Marty Makary may be heading for the scrap heap.
R&D From phase 1 to phase 3: Scaling radiopharmaceutical trials Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
News Hims & Hers to offer unapproved peptides to customers Telehealth firm Hims & Hers will soon start selling some unapproved peptides subject to the FDA's enforcement discretion policy announced last month.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.